PT1187612E - Utilizacao do riluzole para o tratamento da esclerose multipla - Google Patents

Utilizacao do riluzole para o tratamento da esclerose multipla

Info

Publication number
PT1187612E
PT1187612E PT00939007T PT00939007T PT1187612E PT 1187612 E PT1187612 E PT 1187612E PT 00939007 T PT00939007 T PT 00939007T PT 00939007 T PT00939007 T PT 00939007T PT 1187612 E PT1187612 E PT 1187612E
Authority
PT
Portugal
Prior art keywords
riluzole
treatment
multiple sclerosis
utilization
benzothiazolamine
Prior art date
Application number
PT00939007T
Other languages
English (en)
Portuguese (pt)
Inventor
Polman Chris
Original Assignee
Vereniging Voor Christelijk Wetenschappelijk Onderwijs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vereniging Voor Christelijk Wetenschappelijk Onderwijs filed Critical Vereniging Voor Christelijk Wetenschappelijk Onderwijs
Publication of PT1187612E publication Critical patent/PT1187612E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PT00939007T 1999-06-04 2000-06-02 Utilizacao do riluzole para o tratamento da esclerose multipla PT1187612E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99201788 1999-06-04
US17432800P 2000-01-04 2000-01-04

Publications (1)

Publication Number Publication Date
PT1187612E true PT1187612E (pt) 2005-05-31

Family

ID=56290027

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00939007T PT1187612E (pt) 1999-06-04 2000-06-02 Utilizacao do riluzole para o tratamento da esclerose multipla

Country Status (11)

Country Link
EP (2) EP1552831B1 (enExample)
JP (1) JP2003522121A (enExample)
AT (2) ATE287713T1 (enExample)
AU (1) AU777537B2 (enExample)
CA (1) CA2375874A1 (enExample)
DE (1) DE60017733T2 (enExample)
ES (1) ES2235896T3 (enExample)
NZ (1) NZ515685A (enExample)
PT (1) PT1187612E (enExample)
SI (1) SI1187612T1 (enExample)
WO (1) WO2000074676A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1100504A2 (en) 1998-07-02 2001-05-23 Eisai Co., Ltd. Pharmaceutical compositions and their uses for treatment of demyelinating disorders
DE60041365D1 (de) * 1999-06-04 2009-02-26 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Verwendung von Riluzol zur Behandlung Multipler Sklerose
IL136687A0 (en) * 2000-06-12 2001-06-14 Mor Research Applic Ltd Pharmaceutical composition for the treatment of multiple sclerosis
EP1778286A4 (en) * 2004-03-03 2009-04-08 Teva Pharma COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE
ITMI20061274A1 (it) * 2006-06-30 2008-01-01 Consiglio Nazionale Ricerche Vettori nanoparticellari lipidici contenenti riluzolo e composizioni farmaceutiche che li contengono
EP2228054A1 (en) 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
WO2010113225A1 (en) * 2009-03-30 2010-10-07 Yutoku Pharmaceutical Industries Co., Ltd. Riluzole-containing transdermal patch
EA201791110A1 (ru) * 2014-11-21 2017-11-30 Биохэвен Фармасьютикэл Холдинг Компани Лтд. Сублингвальное введение рилузола
BR112017010700A2 (pt) * 2014-11-26 2018-05-08 Medicinova Inc combinação de ibudilaste e riluzol e métodos de uso da mesma

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
AU7298196A (en) * 1995-10-25 1997-05-15 Janssen Pharmaceutica N.V. Infusions of neuroprotectants and perfluorochemicals
CN1202109A (zh) * 1995-11-15 1998-12-16 山之内制药株式会社 红藻氨酸神经细胞毒性抑制剂及吡啶并噻嗪衍生物
US5728728A (en) * 1996-04-10 1998-03-17 Kozachuk; Walter E. Methods of providing neuroprotection
IL119989A0 (en) * 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
JP4120713B2 (ja) * 1997-09-04 2008-07-16 大塚製薬株式会社 多発性硬化症治療剤
DE60041365D1 (de) * 1999-06-04 2009-02-26 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Verwendung von Riluzol zur Behandlung Multipler Sklerose

Also Published As

Publication number Publication date
EP1552831A1 (en) 2005-07-13
ES2235896T3 (es) 2005-07-16
WO2000074676A1 (en) 2000-12-14
EP1187612A1 (en) 2002-03-20
ATE419851T1 (de) 2009-01-15
EP1552831B1 (en) 2009-01-07
ATE287713T1 (de) 2005-02-15
AU777537B2 (en) 2004-10-21
EP1187612B1 (en) 2005-01-26
AU5421900A (en) 2000-12-28
NZ515685A (en) 2002-12-20
CA2375874A1 (en) 2000-12-14
SI1187612T1 (en) 2005-06-30
JP2003522121A (ja) 2003-07-22
DE60017733D1 (de) 2005-03-03
DE60017733T2 (de) 2006-01-12

Similar Documents

Publication Publication Date Title
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
ZA979822B (en) Methods for treating non-suturable, superficial wounds by use of cyanoacrylate ester compositions comprising an antimicrobial agent.
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
AR028512A1 (es) Composiciones antimicrobianas acidas para el tratamiento de alimentos y superficies que contactan alimentos y metodos para la utilizacion de estas
DK1257176T3 (da) Anvendelse af syrestabile proteaser i dyrefoder
MY135766A (en) Quinolinones and naphthyridinones for treating inflammatory diseases
PT1313489E (pt) Composicoes farmaceuticas para o tratamento de mucosite, estomatite e sindroma de behcet
DE10082139T1 (de) Zusammensetzung zur Behandlung von Reibungspaaren
PT755249E (pt) Utilizacao de inibidores da reaccao de maillard para o tratamento de doenca com base em amiloidose
PT1052905E (pt) Processo anti-germinativo de tuberculos e bolbos utilizando o eugenol e/ou o isoeugenol
FI963232L (fi) Antimikrobisena aineena käytettävä hapotettu nitriitti
ES2184077T3 (es) Nuevas fenantridinas sustituidas en la posicion 6.
IL142900A0 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
AU2002367172A1 (en) 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
CY1106234T1 (el) Συνθεσεις για τη θepαπεια μολυνσεων staphylococcus aureus
DE60223576D1 (de) Hautbehandlungszusammensetzung
PT1187612E (pt) Utilizacao do riluzole para o tratamento da esclerose multipla
NO991619L (no) Anvendelse av en H+, K+-ATPase-inhibitor i behandlingen av nesepolypper
PT796618E (pt) Tratamento e profilaxia da pancreatite
TR199900505T2 (enExample)
PT853959E (pt) Composicao para o tratamento do amianto
EE200200693A (et) Interferoon hulgiskleroosi raviks
NZ509051A (en) Chemotaxis-inhibiting protein of staphylococcus (CHIPS) and its use
ZA98420B (en) Use of pramipexole in the treatment of restless legs syndrome.
NO20005548D0 (no) Mykobakterieinhibitorer